Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma--developing measures of response.

Daniel E Furst1, Dinesh Khanna, Marco Mattucci-Cerinic

  • 1University of California at Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu

The Journal of Rheumatology
|December 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lumbar and thoracic inter-vertebral discs: geographical and biological correlates of their variable geometry in Europe.

European journal of radiology·2026
Same author

The role of the microbiome in rheumatoid arthritis: a review.

Rheumatology advances in practice·2024
Same author

Exploring the burden, prevalence and associated factors of chronic musculoskeletal pain in migrants from North Africa and Middle East living in Europe: a scoping review.

BMC public health·2024
Same author

International variation in distribution of ASA class in patients undergoing total hip arthroplasty and its influence on mortality: data from an international consortium of arthroplasty registries.

Acta orthopaedica·2021
Same author

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II.

ACR open rheumatology·2020
Same author

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.

Annals of the rheumatic diseases·2020
Same journal

Clinical and histopathologic characteristics and outcomes of patients with Psoriatic Arthritis undergoing arthroplasty.

The Journal of rheumatology·2026
Same journal

Single-Cell and Spatial Omics Uncover Disease-Specific Synovial Landscapes in Rheumatoid and Psoriatic Arthritis.

The Journal of rheumatology·2026
Same journal

Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies.

The Journal of rheumatology·2026
Same journal

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

The Journal of rheumatology·2026
Same journal

Targeted Therapy, Untargeted Rash: Insights From a GRAPPA Workshop on Immune Shifts in Psoriatic Disease.

The Journal of rheumatology·2026
Same journal

Canadian Rheumatology Association Annual Scientific Meeting Halifax Convention Centre, Halifax, Nova Scotia, Canada, April 16-19, 2026.

The Journal of rheumatology·2026
See all related articles

Researchers are refining outcome measures for scleroderma clinical trials, focusing on gastrointestinal, renal, and vascular issues. Special attention was given to the challenges of pediatric scleroderma research.

Area of Science:

  • Rheumatology and immunology
  • Clinical trial methodology

Background:

  • Scleroderma clinical trials require validated outcome measures for reliable assessment.
  • Previous research has identified key areas needing standardized outcome assessment.

Purpose of the Study:

  • To report on the progress of developing and validating outcome measures for scleroderma at OMERACT 7.
  • To discuss advancements in assessing specific scleroderma manifestations and patient populations.

Main Methods:

  • Discussions and deliberations within a special interest group meeting.
  • Focus on established and emerging assessment tools for various scleroderma complications.

Main Results:

  • Progress was made in evaluating outcome measures for gastrointestinal disease, renal physiology, and vascular damage in scleroderma.

Related Experiment Videos

  • Challenges in assessing pediatric scleroderma were specifically addressed.

    • Conclusions:

    • Continued focus on outcome measure development and validation is crucial for advancing scleroderma research.
    • Addressing specific disease domains and pediatric populations is essential for comprehensive trial design.